A Tale of Two Companies: Matinas Biopharma and Cytodyn
May 2014 first patient dosed with Pro 140
December 2019 BLA nearing completion, FDA approval expected early 2nd quarter 2020
Dec 2014 enrollment
November 2019 Phase 2 started.
Seems to have been abandoned for everything but cryptococcal meningitis
July 2019 Phase 1/2 trial started for cryptococcal meningitis
Both companies with low cash on hand and few assets.
CEO of Matinas, Jerome D. Jabbour's compensation $1.25 million (2018).
CEO of Cytodyn Nader Z. Pourhassan's compensation $837 thousand + 683 thousand bonus $1.52 million (2019).
Yet constant criticism from day 1 about Nader, yet none about Jerome.
CytoDyn Inc (CYDY) Stock Research Links